Figure 2.
IDO1-BIN1-PLXNC1 score predicts AML survival. (A) PLXNC1 mRNA expression value was added to IDO1 and BIN1 mRNA expression values to generate a new signature. The figure shows Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in the HOVON cohort of patients (P < .0001). (B) Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in patients of the HOVON cohort who received chemotherapy alone (P < .001) or (C) received chemotherapy and allogeneic transplantation (P < .05). (D) Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in the TCGA-AML dataset (P < .01). (E) Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in patients of the TCGA-AML dataset who received chemotherapy alone (P < .0001) or (F) who received chemotherapy and allogeneic transplantation (P = not significant).

IDO1-BIN1-PLXNC1 score predicts AML survival. (A) PLXNC1 mRNA expression value was added to IDO1 and BIN1 mRNA expression values to generate a new signature. The figure shows Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in the HOVON cohort of patients (P < .0001). (B) Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in patients of the HOVON cohort who received chemotherapy alone (P < .001) or (C) received chemotherapy and allogeneic transplantation (P < .05). (D) Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in the TCGA-AML dataset (P < .01). (E) Kaplan-Meier estimates of OS according to IDO1-BIN1-PLXNC1 score quartiles in patients of the TCGA-AML dataset who received chemotherapy alone (P < .0001) or (F) who received chemotherapy and allogeneic transplantation (P = not significant).

Close Modal

or Create an Account

Close Modal
Close Modal